Zimmer Biomet Holdings Company Profile (NYSE:ZBH)

About Zimmer Biomet Holdings (NYSE:ZBH)

Zimmer Biomet Holdings logoZimmer Biomet Holdings, Inc. is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products. The Company's products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. The Company manages its operations through three geographic operating segments: the Americas, consisting principally of the United States and other North, Central and South American markets; EMEA, consisting principally of Europe and the Middle East and African markets, and Asia Pacific, consisting primarily of Japan and other Asian and Pacific markets. The Company's product category segments include Americas Spine, Office Based Technologies, Craniomaxillofacial and Thoracic (CMF), and Dental.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Medical Equipment, Supplies & Distribution - NEC
  • Sub-Industry: N/A
  • Symbol: NYSE:ZBH
  • CUSIP: N/A
  • Web: www.zimmerbiomet.com/
  • Market Cap: $25.95 billion
  • Outstanding Shares: 201,644,000
Average Prices:
  • 50 Day Moving Avg: $127.30
  • 200 Day Moving Avg: $120.33
  • 52 Week Range: $95.63 - $133.49
  • Trailing P/E Ratio: 52.66
  • Foreward P/E Ratio: 13.97
  • P/E Growth: 1.58
Sales & Book Value:
  • Annual Revenue: $7.76 billion
  • Price / Sales: 3.34
  • Book Value: $49.27 per share
  • Price / Book: 2.61
  • Annual Dividend: $0.96
  • Dividend Yield: 0.8%
  • EBIDTA: $2.81 billion
  • Net Margins: 15.14%
  • Return on Equity: 12.25%
  • Return on Assets: 4.47%
  • Debt-to-Equity Ratio: 1.06%
  • Current Ratio: 1.91%
  • Quick Ratio: 1.17%
  • Average Volume: 1.48 million shs.
  • Beta: 1.21
  • Short Ratio: 3.17
Frequently Asked Questions for Zimmer Biomet Holdings (NYSE:ZBH)

What is Zimmer Biomet Holdings' stock symbol?

Zimmer Biomet Holdings trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZBH."

How often does Zimmer Biomet Holdings pay dividends? What is the dividend yield for Zimmer Biomet Holdings?

Zimmer Biomet Holdings announced a quarterly dividend on Tuesday, May 30th. Stockholders of record on Friday, June 23rd will be paid a dividend of $0.24 per share on Friday, July 28th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.75%. The ex-dividend date is Wednesday, June 21st. View Zimmer Biomet Holdings' Dividend History.

How were Zimmer Biomet Holdings' earnings last quarter?

Zimmer Biomet Holdings Inc (NYSE:ZBH) posted its quarterly earnings data on Thursday, April, 27th. The company reported $2.13 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.11 by $0.02. The company earned $1.98 billion during the quarter, compared to the consensus estimate of $1.96 billion. Zimmer Biomet Holdings had a return on equity of 12.25% and a net margin of 15.14%. The business's revenue was up 3.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.00 EPS. View Zimmer Biomet Holdings' Earnings History.

When will Zimmer Biomet Holdings make its next earnings announcement?

Zimmer Biomet Holdings is scheduled to release their next quarterly earnings announcement on Thursday, July, 27th 2017. View Earnings Estimates for Zimmer Biomet Holdings.

Where is Zimmer Biomet Holdings' stock going? Where will Zimmer Biomet Holdings' stock price be in 2017?

23 equities research analysts have issued 12 month price targets for Zimmer Biomet Holdings' stock. Their forecasts range from $92.00 to $158.00. On average, they expect Zimmer Biomet Holdings' share price to reach $139.57 in the next twelve months. View Analyst Ratings for Zimmer Biomet Holdings.

What are analysts saying about Zimmer Biomet Holdings stock?

Here are some recent quotes from research analysts about Zimmer Biomet Holdings stock:

  • 1. According to Zacks Investment Research, "Over the last three months, Zimmer Biomet was trading below the Zacks categorized Medical Product industry on factors like macroeconomic uncertainties, pricing pressure and unfavorable currency fluctuations. Situation deteriorated further with the company lowering a disappointing 2017 outlook. According to the company, lower-than-expected manufacturing output of certain legacy Biomet brands during the first quarter 2017 which may lead to declining product availability in the second quarter, required Zimmer Biomet to lower its guidance. However, we are hopeful about the synergy from LDR Holding buyout, which should complement the company’s musculoskeletal offering. Emerging market expansion is another upside." (7/4/2017)
  • 2. Canaccord Genuity analysts commented, "SGEN reported 1Q earnings and provided a pipeline update." (4/28/2017)
  • 3. Needham & Company LLC analysts commented, "We hosted a dinner and investor meetings with Dan Florin, Senior Vice President and CFO, and Bob Marshall, Treasurer and Vice President of Investor Relations this week in New York City. We think that the discussion was upbeat and highlighted ZBH's progress in addressing its manufacturing challenges, its non-recon business performance, margin opportunities, and cash flow outlook. The meetings reinforced our view that ZBH should be able to drive its revenue growth to sustainable mid-single digit growth with a combination of market growth in recon and above-market growth in its non-recon businesses. We reiterate our Strong Buy rating." (2/17/2017)
  • 4. J P Morgan Chase & Co analysts commented, "Zimmer’s re-acceleration continued into 2Q earnings as sales grew 4.5% pro- forma and 2.6% organic excluding an extra selling day. Organic growth came in well above the Street’s call for 1.6% organic growth and buy-side calls for 1.9% (see our recent survey here). The sales beat was broad based with each business performing in-line or better than Street estimates with Knees (+$2M), Hips (+$9M), SET (+$20M), and Dental (+$5M) as the standout performers in the quarter. While gross margins were lower than expected (70bps), this was tempered by in-line operating expense and a better than expected tax rate including benefits from the early adoption of ASU 2016-09 (+$0.01). When factoring in the better than expected top-line, this drove a $0.05 Cash EPS beat. With Zimmer’s turnaround tracking ahead of expectations, we reiterate our Overweight rating on the stock and raise our price target from $134 to $148 (Y/E 17), conservatively valuing the stock at 15x 2018 Cash EPS, a 20% discount to its peers." (7/29/2016)

Who are some of Zimmer Biomet Holdings' key competitors?

Who are Zimmer Biomet Holdings' key executives?

Zimmer Biomet Holdings' management team includes the folowing people:

  • Daniel P. Florin, Interim Chief Executive Officer, Chief Financial Officer, Director
  • Robert D. Delps, President, Americas
  • Katarzyna Mazur-Hofsaess M.D. Ph.D., President, Europe, Middle East and Africa
  • Sang Yi, President, Asia Pacific
  • Chad F. Phipps, Senior Vice President, General Counsel, Secretary
  • Larry C. Glasscock, Independent Non-Executive Chairman of the Board
  • Christopher B. Begley, Independent Director
  • Betsy J. Bernard, Independent Director
  • Gail Koziara Boudreaux, Independent Director
  • Michael Farrell, Independent Director

Who owns Zimmer Biomet Holdings stock?

Zimmer Biomet Holdings' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Longview Partners Guernsey LTD (3.16%), Focused Investors LLC (0.57%), Factory Mutual Insurance Co. (0.26%), Russell Investments Group Ltd. (0.26%), Hexavest Inc. (0.15%) and Bank of Montreal Can (0.09%). Company insiders that own Zimmer Biomet Holdings stock include Blackstone Capital Partners V, Chad F Phipps, Daniel E Williamson, Daniel P Florin, David A Jr Nolan, David C Dvorak, Sang Yi, Stuart G Kleopfer and Tony W Collins. View Institutional Ownership Trends for Zimmer Biomet Holdings.

Who sold Zimmer Biomet Holdings stock? Who is selling Zimmer Biomet Holdings stock?

Zimmer Biomet Holdings' stock was sold by a variety of institutional investors in the last quarter, including Focused Investors LLC, Sit Investment Associates Inc., APG Asset Management N.V., Russell Investments Group Ltd., Affinity Investment Advisors LLC, Hexavest Inc., Exxonmobil Investment Management Inc. TX and US Bancorp DE. Company insiders that have sold Zimmer Biomet Holdings stock in the last year include Chad F Phipps, Daniel E Williamson, David A Jr Nolan, David C Dvorak, Sang Yi, Stuart G Kleopfer and Tony W Collins. View Insider Buying and Selling for Zimmer Biomet Holdings.

Who bought Zimmer Biomet Holdings stock? Who is buying Zimmer Biomet Holdings stock?

Zimmer Biomet Holdings' stock was bought by a variety of institutional investors in the last quarter, including Longview Partners Guernsey LTD, Ferguson Wellman Capital Management Inc., Bank of Montreal Can, Mn Services Vermogensbeheer B.V., BTIM Corp., National Pension Service, ING Groep NV and Mitsubishi UFJ Asset Management UK Ltd.. View Insider Buying and Selling for Zimmer Biomet Holdings.

How do I buy Zimmer Biomet Holdings stock?

Shares of Zimmer Biomet Holdings can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zimmer Biomet Holdings' stock price today?

One share of Zimmer Biomet Holdings stock can currently be purchased for approximately $128.70.

MarketBeat Community Rating for Zimmer Biomet Holdings (NYSE ZBH)
Community Ranking:  2.9 out of 5 ( )
Outperform Votes:  505 (Vote Outperform)
Underperform Votes:  367 (Vote Underperform)
Total Votes:  872
MarketBeat's community ratings are surveys of what our community members think about Zimmer Biomet Holdings and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Zimmer Biomet Holdings (NYSE:ZBH) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 5 Hold Ratings, 16 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.74)
Consensus Price Target: $139.57 (8.45% upside)

Analysts' Ratings History for Zimmer Biomet Holdings (NYSE:ZBH)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/17/2017Morgan StanleyBoost Price TargetOverweight$137.00 -> $150.00LowView Rating Details
7/14/2017Piper Jaffray CompaniesReiterated RatingBuy$141.00LowView Rating Details
7/14/2017Stifel NicolausReiterated RatingHold$125.00LowView Rating Details
7/14/2017Bank of America CorporationReiterated RatingBuy -> Buy$158.00MediumView Rating Details
7/14/2017Wells Fargo & CompanyReiterated RatingMarket WeightHighView Rating Details
7/14/2017Royal Bank Of CanadaReiterated RatingOutperform$140.00HighView Rating Details
7/14/2017Canaccord GenuityReiterated RatingBuy$141.00HighView Rating Details
7/12/2017Needham & Company LLCReiterated RatingStrong-Buy$153.00LowView Rating Details
7/12/2017GuggenheimUpgradeNeutral -> Buy$157.00MediumView Rating Details
7/11/2017BMO Capital MarketsReiterated RatingBuy$136.00LowView Rating Details
6/30/2017Jefferies Group LLCReiterated RatingBuy$148.00LowView Rating Details
6/29/2017Cantor FitzgeraldInitiated CoverageNeutral -> Neutral$137.00LowView Rating Details
6/9/2017Citigroup Inc.Boost Price TargetNeutral$108.00 -> $130.00LowView Rating Details
5/16/2017Goldman Sachs Group, Inc. (The)Initiated CoverageSell -> Sell$92.00HighView Rating Details
4/28/2017Oppenheimer Holdings, Inc.Set Price TargetBuy$132.00LowView Rating Details
2/1/2017Robert W. BairdReiterated RatingOutperform$130.00 -> $136.00N/AView Rating Details
1/5/2017J P Morgan Chase & CoSet Price TargetBuy$134.00N/AView Rating Details
11/8/2016Northcoast ResearchDowngradeBuy -> NeutralN/AView Rating Details
11/1/2016Leerink SwannReiterated RatingOutperform$150.00 -> $136.00N/AView Rating Details
9/22/2016ArgusReiterated RatingBuy$140.00N/AView Rating Details
8/23/2016Barclays PLCBoost Price TargetOverweight$140.00 -> $145.00N/AView Rating Details
8/11/2016SunTrust Banks, Inc.Initiated CoverageBuy$155.00N/AView Rating Details
7/29/2016JMP SecuritiesBoost Price TargetMarket Outperform$131.00 -> $145.00N/AView Rating Details
5/16/2016Sterne Agee CRTReiterated RatingBuyN/AView Rating Details
3/17/2016NomuraInitiated CoverageBuy$123.00N/AView Rating Details
1/31/2016William BlairReiterated RatingOutperformN/AView Rating Details
1/29/2016Northland SecuritiesLower Price Target$109.00 -> $105.00N/AView Rating Details
10/30/2015Brean CapitalReiterated RatingHoldN/AView Rating Details
10/9/2015Credit Suisse GroupInitiated CoverageOutperform$107.00N/AView Rating Details
7/29/2015Deutsche Bank AGReiterated RatingHold$114.00N/AView Rating Details
(Data available from 7/26/2015 forward)


Earnings History for Zimmer Biomet Holdings (NYSE:ZBH)
Earnings by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)
Earnings History by Quarter for Zimmer Biomet Holdings (NYSE ZBH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/27/2017Q2 2017$2.11N/AView Earnings Details
4/27/2017Q1 2017$2.11$2.13$1.96 billion$1.98 billionViewN/AView Earnings Details
1/31/2017Q416$2.11$2.14$1.98 billion$2.01 billionViewListenView Earnings Details
10/31/2016Q316$1.79$1.79$950.20 million$1.83 billionViewListenView Earnings Details
7/28/2016Q216$1.97$2.02$1.90 billion$1.93 billionViewListenView Earnings Details
4/28/2016Q116$1.93$2.00$1.88 billion$1.90 billionViewListenView Earnings Details
1/28/2016Q415$2.04$2.09$1.96 billion$1.98 billionViewListenView Earnings Details
10/29/2015Q315$1.56$1.64$1.76 billion$1.76 billionViewListenView Earnings Details
4/30/2015Q115$1.54$1.58$1.15 billion$1.13 billionViewN/AView Earnings Details
1/29/2015Q414$1.71$0.91$1.25 billion$1.22 billionViewN/AView Earnings Details
10/23/2014Q314$1.00$0.96$1.10 billion$1.11 billionViewListenView Earnings Details
7/24/2014Q214$1.49$1.49$1.21 billion$1.18 billionViewN/AView Earnings Details
4/24/2014Q114$1.47$1.50$1.18 billion$1.16 billionViewListenView Earnings Details
1/31/2014Q114$1.62$1.36$1.22 billion$1.24 billionViewN/AView Earnings Details
10/24/2013Q313$1.24$1.25$1.06 billion$1.07 billionViewN/AView Earnings Details
7/25/2013Q2 2013$1.44$1.43$1.15 billion$1.17 billionViewN/AView Earnings Details
4/25/2013Q1 2013$1.40$1.41$1.14 billion$1.14 billionViewN/AView Earnings Details
1/31/2013Q4 2012$1.49$1.51$1.17 billion$1.18 billionViewN/AView Earnings Details
10/25/2012$1.13$1.15ViewN/AView Earnings Details
7/26/2012$1.32$1.34ViewN/AView Earnings Details
4/26/2012$1.30$1.30ViewN/AView Earnings Details
1/26/2012$1.34$1.36ViewN/AView Earnings Details
10/27/2011$1.03$1.04ViewN/AView Earnings Details
7/27/2011$1.19$1.21ViewN/AView Earnings Details
4/28/2011$1.12$1.19ViewN/AView Earnings Details
1/27/2011$1.19$1.21ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Zimmer Biomet Holdings (NYSE:ZBH)
2017 EPS Consensus Estimate: $8.54
2018 EPS Consensus Estimate: $9.37
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20175$2.10$2.14$2.11
Q2 20176$2.08$2.18$2.12
Q3 20176$1.89$2.01$1.95
Q4 20176$2.32$2.41$2.36
Q1 20183$2.25$2.32$2.29
Q2 20183$2.25$2.39$2.32
Q3 20182$2.12$2.18$2.15
Q4 20182$2.59$2.63$2.61
(Data provided by Zacks Investment Research)


Current Dividend Information for Zimmer Biomet Holdings (NYSE:ZBH)
Next Dividend:7/28/2017
Annual Dividend:$0.96
Dividend Yield:0.75%
Dividend Growth:0.00% (3 Year Average)
Payout Ratio:39.67% (Trailing 12 Months of Earnings)
11.28% (Based on This Year's Estimates)
10.42% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Dividend History by Quarter for Zimmer Biomet Holdings (NYSE ZBH)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Zimmer Biomet Holdings (NYSE:ZBH)
Insider Ownership Percentage: 1.07%
Institutional Ownership Percentage: 84.37%
Insider Trades by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)
Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)
Insider Trades by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/12/2017Sang YiInsiderSell17,731$124.56$2,208,573.36View SEC Filing  
5/5/2017Chad F. PhippsVPSell6,200$116.76$723,912.00View SEC Filing  
4/27/2017David C DvorakInsiderSell87,331$116.47$10,171,441.57View SEC Filing  
3/20/2017David C DvorakInsiderSell1,040$121.63$126,495.20View SEC Filing  
12/2/2016David A. Jr. NolanInsiderSell5,050$101.11$510,605.50View SEC Filing  
9/8/2016Daniel E WilliamsonInsiderSell2,716$129.96$352,971.36View SEC Filing  
8/23/2016Stuart G KleopferInsiderSell3,397$129.71$440,624.87View SEC Filing  
8/12/2016Tony W. CollinsVPSell1,287$129.16$166,228.92View SEC Filing  
8/9/2016Stuart G KleopferInsiderSell533$132.71$70,734.43View SEC Filing  
8/1/2016David A. Jr. NolanInsiderSell25,255$130.77$3,302,596.35View SEC Filing  
7/11/2016Daniel P FlorinCFOSell15,000$124.98$1,874,700.00View SEC Filing  
6/14/2016Tony W CollinsCAOSell3,611$116.43$420,428.73View SEC Filing  
6/9/2016Stuart G KleopferInsiderSell11,000$119.45$1,313,950.00View SEC Filing  
4/14/2016Daniel P FlorinCFOSell10,000$114.98$1,149,800.00View SEC Filing  
4/12/2016Daniel P FlorinCFOSell12,000$110.00$1,320,000.00View SEC Filing  
3/21/2016David C DvorakCEOSell1,540$104.16$160,406.40View SEC Filing  
2/10/2016Blackstone Capital Partners VMajor ShareholderSell7,351,708$95.91$705,102,314.28View SEC Filing  
1/8/2016David C. DvorakCEOSell44,661$102.46$4,575,966.06View SEC Filing  
12/2/2015David A. Jr. NolaninsiderSell3,435$102.62$352,499.70View SEC Filing  
6/30/2015Adam Rudolph JohnsonInsiderSell30,600$110.34$3,376,404.00View SEC Filing  
6/29/2015Daniel E WilliamsonInsiderSell16,000$110.98$1,775,680.00View SEC Filing  
6/29/2015Daniel P FlorinCFOSell5,000$107.00$535,000.00View SEC Filing  
3/17/2015David C DvorakCEOSell1,300$115.55$150,215.00View SEC Filing  
12/5/2014David C DvorakCEOSell48,703$115.00$5,600,845.00View SEC Filing  
11/28/2014Chad F PhippsVPSell5,000$112.00$560,000.00View SEC Filing  
11/3/2014Katarzyna Mazur-HofsaessInsiderSell28,253$110.01$3,108,112.53View SEC Filing  
9/9/2014Stephen Hong Liang OoiInsiderSell40,768$102.78$4,190,135.04View SEC Filing  
8/26/2014James T CrinesCFOSell40,768$101.00$4,117,568.00View SEC Filing  
1/8/2014Jeffery MccaulleyInsiderSell21,286$96.00$2,043,456.00View SEC Filing  
1/7/2014Chad PhippsVPSell7,000$95.00$665,000.00View SEC Filing  
12/20/2013Jeffery MccaulleyInsiderSell21,286$93.00$1,979,598.00View SEC Filing  
12/3/2013Jeffery MccaulleyInsiderSell2,713$90.12$244,495.56View SEC Filing  
11/15/2013Derek DavisCAOSell3,500$90.20$315,700.00View SEC Filing  
11/14/2013Chad PhippsVPSell7,800$90.00$702,000.00View SEC Filing  
11/14/2013David DvorakCEOSell64,763$90.00$5,828,670.00View SEC Filing  
11/14/2013Jeffery MccaulleyInsiderSell21,285$90.00$1,915,650.00View SEC Filing  
9/13/2013Katarzyna Mazur-HofsaessInsiderSell4,890$81.38$397,948.20View SEC Filing  
8/1/2013James T CrinesCFOSell46,200$84.56$3,906,672.00View SEC Filing  
8/1/2013Stephen Hong Liang OoiInsiderSell38,500$84.27$3,244,395.00View SEC Filing  
7/29/2013Derek M DavisCAOSell3,725$83.78$312,080.50View SEC Filing  
7/29/2013Jeffery A MccaulleyInsiderSell112,255$83.40$9,362,067.00View SEC Filing  
7/19/2013Chad F PhippsVPSell6,000$83.00$498,000.00View SEC Filing  
5/8/2013Chad F PhippsVPSell5,000$77.26$386,300.00View SEC Filing  
4/30/2013James T CrinesCFOSell25,000$76.08$1,902,000.00View SEC Filing  
4/30/2013Jeffery A MccaulleyInsiderSell10,000$76.08$760,800.00View SEC Filing  
2/4/2013Derek M DavisCAOSell21,864$72.53$1,585,795.92View SEC Filing  
2/4/2013Jeffery A MccaulleyInsiderSell12,000$73.60$883,200.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Zimmer Biomet Holdings (NYSE:ZBH)
Latest Headlines for Zimmer Biomet Holdings (NYSE:ZBH)
americanbankingnews.com logoZimmer Biomet Holdings, Inc. (ZBH) Downgraded to "Hold" at BidaskClub
www.americanbankingnews.com - July 24 at 11:32 PM
finance.yahoo.com logoJana Partners Cleans Up, Exits Whole Foods Stake
finance.yahoo.com - July 21 at 9:00 AM
americanbankingnews.com logoZimmer Biomet Holdings, Inc. (NYSE:ZBH) to Release Quarterly Earnings on Thursday
www.americanbankingnews.com - July 20 at 7:44 AM
finance.yahoo.com logoCramer explains why CEO departures are not always bad for...
finance.yahoo.com - July 18 at 4:30 AM
finance.yahoo.com logoZimmer Biomet: Cramer's Top Takeaways
finance.yahoo.com - July 17 at 11:27 PM
finance.yahoo.com logoCramer explains why CEO departures are not always bad for companies
finance.yahoo.com - July 17 at 6:25 PM
americanbankingnews.com logoMorgan Stanley Increases Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Price Target to $150.00
www.americanbankingnews.com - July 17 at 5:58 PM
americanbankingnews.com logoZimmer Biomet Holdings, Inc. (NYSE:ZBH) Given "Hold" Rating at Stifel Nicolaus
www.americanbankingnews.com - July 15 at 10:34 AM
americanbankingnews.com logoZimmer Biomet Holdings, Inc. (NYSE:ZBH) Stock Rating Reaffirmed by Piper Jaffray Companies
www.americanbankingnews.com - July 15 at 9:44 AM
americanbankingnews.com logoZimmer Biomet Holdings, Inc. (NYSE:ZBH) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - July 14 at 12:40 PM
americanbankingnews.com logoZimmer Biomet Holdings, Inc. (ZBH) Rating Reiterated by Canaccord Genuity
www.americanbankingnews.com - July 14 at 12:32 PM
americanbankingnews.com logoZimmer Biomet Holdings' (ZBH) "Buy" Rating Reaffirmed at Bank of America Corporation
www.americanbankingnews.com - July 14 at 12:03 PM
americanbankingnews.com logoZimmer Biomet Holdings, Inc. (NYSE:ZBH) Earns Market Weight Rating from Wells Fargo & Company
www.americanbankingnews.com - July 14 at 10:44 AM
americanbankingnews.com logoRoyal Bank Of Canada Reaffirms "Outperform" Rating for Zimmer Biomet Holdings, Inc. (NYSE:ZBH)
www.americanbankingnews.com - July 14 at 10:18 AM
americanbankingnews.com logoQ2 2017 EPS Estimates for Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Decreased by Analyst
www.americanbankingnews.com - July 14 at 8:38 AM
nasdaq.com logoStryker awarded $248.7 million in patent case against Zimmer ... - Nasdaq
www.nasdaq.com - July 14 at 1:37 AM
finance.yahoo.com logoJana granted regulatory clearance for Zimmer Biomet stake
finance.yahoo.com - July 13 at 8:35 PM
finance.yahoo.com logoZimmer Biomet Stock Jumps After Jana Said to Have Taken Significant Stake
finance.yahoo.com - July 13 at 3:32 PM
nasdaq.com logoZimmer Biomet's Preliminary Q2 Numbers Solid, CEO Steps Down
www.nasdaq.com - July 13 at 11:32 AM
finance.yahoo.com logoWhat CEO Departure Means for Zimmer Biomet
finance.yahoo.com - July 13 at 11:32 AM
finance.yahoo.com logoAnalysts Applaud Zimmer CEO Departure
finance.yahoo.com - July 13 at 11:32 AM
finance.yahoo.com logoMedtech CEO Hits 'Third Strike,' Steps Down On Q2 Disappointment
finance.yahoo.com - July 13 at 11:32 AM
finance.yahoo.com logoZimmer Biomet's Preliminary Q2 Numbers Solid, CEO Steps Down
finance.yahoo.com - July 13 at 11:32 AM
finance.yahoo.com logoStryker awarded $248.7 million in patent case against Zimmer
finance.yahoo.com - July 13 at 11:32 AM
americanbankingnews.com logoZimmer Biomet Holdings, Inc. (NYSE:ZBH) Expected to Post Quarterly Sales of $1.95 Billion
www.americanbankingnews.com - July 13 at 10:02 AM
americanbankingnews.com logoZimmer Biomet Holdings' (ZBH) "Strong-Buy" Rating Reiterated at Needham & Company LLC
www.americanbankingnews.com - July 12 at 3:41 PM
nasdaq.com logoZimmer Biomet CEO Steps Down; Sees Q2 Adj. EPS At Or Near Bottom Of Prior Range
www.nasdaq.com - July 12 at 1:23 AM
americanbankingnews.com logo Analysts Anticipate Zimmer Biomet Holdings, Inc. (ZBH) Will Post Earnings of $2.11 Per Share
www.americanbankingnews.com - July 12 at 12:06 AM
streetinsider.com logoZimmer Biomet Holdings (ZBH) CEO Steps Down - StreetInsider.com
www.streetinsider.com - July 11 at 8:23 PM
finance.yahoo.com logoZimmer Biomet Announces Leadership Transition
finance.yahoo.com - July 11 at 8:22 PM
finance.yahoo.com logoZimmer Biomet Reports Certain Preliminary Second Quarter 2017 Results
finance.yahoo.com - July 11 at 8:22 PM
finance.yahoo.com logoZimmer Biomet shares slide on CEO departure, outlook
finance.yahoo.com - July 11 at 8:22 PM
americanbankingnews.com logoQ4 2018 EPS Estimates for Zimmer Biomet Holdings, Inc. (ZBH) Raised by Analyst
www.americanbankingnews.com - July 10 at 9:44 AM
finance.yahoo.com logo[$$] Hans Zimmer, Movie Maestro
finance.yahoo.com - July 8 at 8:40 AM
americanbankingnews.com logoZimmer Biomet Holdings, Inc. to Post Q2 2018 Earnings of $2.25 Per Share, SunTrust Banks Forecasts (NYSE:ZBH)
www.americanbankingnews.com - July 4 at 12:39 PM
americanbankingnews.com logoZimmer Biomet Holdings, Inc. (ZBH) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - July 4 at 11:42 AM
americanbankingnews.com logoCantor Fitzgerald Comments on Zimmer Biomet Holdings, Inc.'s FY2017 Earnings (NYSE:ZBH)
www.americanbankingnews.com - July 4 at 7:30 AM
finance.yahoo.com logoZimmer Biomet Stock Regains Momentum: What’s Driving Growth?
finance.yahoo.com - July 1 at 9:21 AM
finance.yahoo.com logoZimmer Biomet Expands Portfolio with X-Ray–Based Knee System
finance.yahoo.com - July 1 at 9:21 AM
finance.yahoo.com logoFDA Warning Letter to Zimmer Biomet Resolved, Boosts Confidence
finance.yahoo.com - July 1 at 9:21 AM
finance.yahoo.com logoETFs with exposure to Zimmer Biomet Holdings, Inc. : June 30, 2017
finance.yahoo.com - July 1 at 9:21 AM
finance.yahoo.com logoZimmer Biomet Holdings Announces Live Audio Webcast and Conference Call of Second Quarter 2017 Results
finance.yahoo.com - July 1 at 9:21 AM
americanbankingnews.com logoZimmer Biomet Holdings, Inc. (ZBH) Receives Buy Rating from Jefferies Group LLC
www.americanbankingnews.com - June 30 at 8:02 AM
nasdaq.com logoInvacare Corporation (IVC) Ex-Dividend Date Scheduled for June 29, 2017 - Nasdaq
www.nasdaq.com - June 29 at 9:35 PM
americanbankingnews.com logoZimmer Biomet Holdings, Inc. (ZBH) Earns Neutral Rating from Analysts at Cantor Fitzgerald
www.americanbankingnews.com - June 29 at 6:02 PM
finance.yahoo.com logoZimmer Biomet (ZBH) Launches X-Ray-Based X-PSI Knee System
finance.yahoo.com - June 29 at 4:30 PM
finance.yahoo.com logoZimmer Biomet Introduces the World's First CE Marked, X-Ray-Based Patient Specific Instrument System for Total Knee Replacement Surgery
finance.yahoo.com - June 29 at 8:15 AM
nasdaq.com logoZimmer Biomet Holdings, Inc. (ZBH) Ex-Dividend Date Scheduled for June 21, 2017 - Nasdaq
www.nasdaq.com - June 20 at 3:46 PM
finance.yahoo.com logoETFs with exposure to Zimmer Biomet Holdings, Inc. : June 20, 2017
finance.yahoo.com - June 20 at 3:45 PM
finance.yahoo.com logoZimmer Biomet Holdings, Inc. :ZBH-US: Earnings Analysis: Q1, 2017 By the Numbers : June 19, 2017
finance.yahoo.com - June 20 at 9:28 AM



Zimmer Biomet Holdings (ZBH) Chart for Wednesday, July, 26, 2017

This page was last updated on 7/26/2017 by MarketBeat.com Staff